Clinical trial of a typhoid vaccine candidate under joint development with the International Vaccine Institute
(Seoul = Yonhap News) Reporter Kim Jan-di = SK Bioscience[302440]announced on the 28th that it has confirmed the booster shot effect of ‘NBP618’, a typhoid vaccine candidate being jointly developed with the International Vaccine Institute (IVI).
This is according to a phase 2 clinical trial jointly conducted in the Philippines by SK Bioscience, IVI, and the Institute of Tropical Medicine in Manila, Philippines, from April 2018 to October 2020.
The research team analyzed the immune effects of ‘NBP618’ following administering a booster shot of ‘NBP618’ to 285 infants 6 to 23 months of age who received a single primary vaccination once morest typhoid.
As a result of administering the booster shot 27.5 months following the first inoculation, it was confirmed that a strong immune response was induced, such as a 64-fold increase in antibody titer in the body.
The research results were published online in the Nature partner journal Vaccines, a sister journal of Nature.
NBP618 is a typhoid conjugate vaccine candidate that SK Bioscience is developing together with IVI with the aim of supplying it to overseas markets such as underdeveloped countries. The efficacy was confirmed in the phase 3 clinical trial, showing an immune response comparable to that of the existing typhoid vaccine. In January of last year, the Ministry of Food and Drug Safety applied for an export product license and is waiting for the results.
(Seoul = Yonhap News) SK Bioscience Researcher. 2022.02.28. [SK바이오사이언스 제공. 재판매 및 DB 금지]
jandi@yna.co.kr
Report on Kakao Talk okjebo
<저작권자(c) 연합뉴스,
Unauthorized reproduction-redistribution prohibited>
2022/02/28 10:03 Send
